Proactive Risk Evaluation for Cardiac Implantable Electronic Device Strategy Using AI-ECG
Recruiting
N/A
Interventional Study
Artificial Intelligence (AI)
Cardiac Implantable Electrical Devices
Conduction Disorder of the Heart
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 65 – 90
- Sex
- Any
- Study type
- Interventional
- Purpose
- Screening
- Participants needed
- 11,492 (estimated)
- Sponsor
- National Defense Medical Center, Taiwan · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn whether an artificial intelligence-enhanced electrocardiogram (AI-ECG) strategy improves timely intervention of patients requiring cardiac implantable electronic devices (CIEDs), compared with standard clinical care.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* At least one 12-lead ECG within 1 year
Exclusion Criteria:
* Diagnosis of sick sinus syndrome
* Diagnosis of high-grade or complete atrioventricular block
* Diagnosis of ventricular tachycardia or ventricular fibrillation
* Post CIED implant
* Heart rate below 40 beats per m…
Contacts